Complementary roles of surgery and systemic treatment in clear cell renal cell carcinoma

医学 肾细胞癌 全身疗法 肿瘤科 疾病 免疫疗法 临床试验 内科学 肾癌 肾切除术 新辅助治疗 癌症 外科 重症监护医学 乳腺癌
作者
Alexandre Ingels,Riccardo Campi,Umberto Capitanio,Daniele Amparore,Riccardo Schiavina,Umberto Carbonara,Selçuk Erdem,Önder Kara,Tobias Klatte,Maximilian C. Kriegmair,Michele Marchioni,M.C. Mir,I. Ouzaïd,Nicola Pavan,Angela Pecoraro,Eduard Roussel,Alexandre de la Taille
出处
期刊:Nature Reviews Urology [Springer Nature]
卷期号:19 (7): 391-418 被引量:31
标识
DOI:10.1038/s41585-022-00592-3
摘要

Standard-of-care management of renal cell carcinoma (RCC) indisputably relies on surgery for low-risk localized tumours and systemic treatment for poor-prognosis metastatic disease, but a grey area remains, encompassing high-risk localized tumours and patients with metastatic disease with a good-to-intermediate prognosis. Over the past few years, results of major practice-changing trials for the management of metastatic RCC have completely transformed the therapeutic options for this disease. Treatments targeting vascular endothelial growth factor (VEGF) have been the mainstay of therapy for metastatic RCC in the past decade, but the advent of immune checkpoint inhibitors has revolutionized the therapeutic landscape in the metastatic setting. Results from several pivotal trials have shown a substantial benefit from the combination of VEGF-directed therapy and immune checkpoint inhibition, raising new hopes for the treatment of high-risk localized RCC. The potential of these therapeutics to facilitate the surgical extirpation of the tumour in the neoadjuvant setting or to improve disease-free survival in the adjuvant setting has been investigated. The role of surgery for metastatic RCC has been redefined, with results of large trials bringing into question the paradigm of upfront cytoreductive nephrectomy, inherited from the era of cytokine therapy, when initial extirpation of the primary tumour did show clinical benefits. The potential benefits and risks of deferred surgery for residual primary tumours or metastases after partial response to checkpoint inhibitor treatment are also gaining interest, considering the long-lasting effects of these new drugs, which encourages the complete removal of residual masses.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
2秒前
桐桐应助elastin采纳,获得10
3秒前
5秒前
6秒前
林钰浩发布了新的文献求助10
7秒前
LIGHT完成签到,获得积分10
7秒前
梁慧芳发布了新的文献求助30
8秒前
9秒前
喵呜完成签到,获得积分20
10秒前
章鱼哥完成签到,获得积分10
10秒前
zhangqq完成签到,获得积分10
13秒前
咯噔完成签到,获得积分10
15秒前
林钰浩完成签到,获得积分10
15秒前
不觉晚风完成签到,获得积分10
16秒前
17秒前
追寻的忆山完成签到,获得积分10
19秒前
白芍完成签到,获得积分10
20秒前
今后应助哈比人linling采纳,获得10
22秒前
帅气的如豹完成签到,获得积分20
25秒前
华仔应助科研通管家采纳,获得10
27秒前
科研通AI2S应助科研通管家采纳,获得10
27秒前
乐乐应助科研通管家采纳,获得10
27秒前
Akim应助科研通管家采纳,获得10
28秒前
FashionBoy应助科研通管家采纳,获得10
28秒前
大个应助科研通管家采纳,获得10
28秒前
万刈应助科研通管家采纳,获得10
28秒前
英俊的铭应助科研通管家采纳,获得30
28秒前
科目三应助科研通管家采纳,获得10
28秒前
领导范儿应助科研通管家采纳,获得10
28秒前
29秒前
明越发布了新的文献求助30
29秒前
29秒前
32秒前
李健的粉丝团团长应助sj采纳,获得10
32秒前
34秒前
镜哥完成签到,获得积分10
35秒前
小明日天发布了新的文献求助10
35秒前
聪慧海蓝完成签到,获得积分10
35秒前
高分求助中
The ACS Guide to Scholarly Communication 2500
Sustainability in Tides Chemistry 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Genera Insectorum: Mantodea, Fam. Mantidæ, Subfam. Hymenopodinæ (Classic Reprint) 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3082546
求助须知:如何正确求助?哪些是违规求助? 2735785
关于积分的说明 7538956
捐赠科研通 2385412
什么是DOI,文献DOI怎么找? 1264844
科研通“疑难数据库(出版商)”最低求助积分说明 612817
版权声明 597672